FGM - ETF AI Analysis
Top Page
First Trust Germany AlphaDEX Fund (FGM)
FGM, the First Trust Germany AlphaDEX Fund, earns a solid overall rating thanks to strong contributions from holdings like Volkswagen and Aurubis, which combine robust financial performance with attractive valuations and positive technical trends. However, weaker names such as Delivery Hero and Bayer, which face profitability challenges, high leverage, and valuation concerns, weigh on the fund’s score. The main risk factor is its concentrated exposure to German companies, meaning economic or market stress in Germany could impact many holdings at once.
FGM vs. SPDR S&P 500 ETF (SPY)
- AUM
- 87.22M
- Region
- Europe
- Expense Ratio
- 0.80%
- Beta
- 0.79
- Issuer
- First Trust
- Inception Date
- Feb 14, 2012
- Dividend Yield
- 1.86%
- Asset Class
- Equity
- Index Tracked
- NASDAQ AlphaDEX Germany Index
FGM Summary
FGM is an exchange-traded fund that focuses on German stocks, following the NASDAQ AlphaDEX Germany Index. Instead of just buying the biggest companies, it uses a rules-based approach to pick German firms with strong growth and value potential. It holds well-known names like Volkswagen, Porsche, Bayer, and BMW, giving investors broad exposure to one of Europe’s key economies in a single investment. Someone might invest in FGM to diversify internationally and seek long-term growth from German industry and innovation. A key risk is that the fund’s value can rise or fall sharply with the German stock market.
How much will it cost me?
This ETF has an expense ratio of 0.80%, which means you’ll pay about $8 per year for every $1,000 you invest. That’s higher than the average ETF cost because FGM is actively managed using the AlphaDEX strategy rather than simply tracking a basic market index.
What would affect this ETF?
FGM could benefit if Germany’s economy strengthens, especially in consumer and industrial sectors, and if European interest rates stay supportive of business investment, helping major holdings like BMW, Porsche, and Volkswagen. On the downside, weaker European growth, higher interest rates, or stricter regulations on autos, technology, and materials could hurt profits for its top German companies and weigh on the fund’s performance.
FGM Top 10 Holdings
FGM is essentially a bet on Germany’s industrial and consumer backbone, with autos and materials setting the tone. Porsche, BMW, and Volkswagen have been lagging lately, so the fund’s engine is sputtering on the car side, while Vonovia’s weak real estate performance adds more drag. On the brighter side, Delivery Hero is rising and Aurubis has been on a firmer footing, helping offset some of that pressure, with Bayer and Fresenius more steady than spectacular. Overall, it’s a Germany-heavy, cyclical-tilted portfolio with little global diversification.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 DE:DHER | Delivery Hero SE | 4.58% | $3.95M | EUR 11.55B | 64.75% | 50Neutral |
 BAMXF | Bayerische Motoren Werke Aktiengesellschaft | ― | ― | ― | ― | 71Outperform |
 DE:TKA | thyssenkrupp | 4.08% | $3.51M | EUR 7.48B | 28.70% | 59Neutral |
 DE:PAH3 | Porsche Automobil Holding | 4.19% | $3.61M | EUR 7.84B | -26.18% | 55Neutral |
 DE:FME | Fresenius Medical Care AG & Co. KGaA | 3.61% | $3.11M | EUR 10.73B | -13.32% | 64Neutral |
 DE:UTDI | United Internet | 3.69% | $3.18M | EUR 4.48B | -12.73% | 62Neutral |
 DE:VOW3 | Volkswagen | 3.51% | $3.03M | EUR 34.76B | -22.85% | 82Outperform |
 DE:BAYN | Bayer | 3.69% | $3.18M | EUR 49.69B | 88.24% | 54Neutral |
 DE:NDA | Aurubis | 3.27% | $2.82M | EUR 5.86B | 16.90% | 74Outperform |
 DE:HOT | Hochtief | 3.25% | $2.80M | EUR 28.13B | 47.75% | 69Neutral |
FGM Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FGM, the sentiment is Negative. The current price of 57.54 is above the 20-day moving average (MA) of 57.47, below the 50-day MA of 60.29, and below the 200-day MA of 62.74, indicating a neutral trend. The MACD of -0.70 indicates Negative momentum. The RSI at 44.07 is Neutral, neither overbought nor oversold. The STOCH value of 71.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FGM.
FGM Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FGM | $57.54 | $62.00(7.76% Upside) | $87.22M | 0.80% | 66Neutral |
 EWG | $41.88 | $50.03(19.47% Upside) | $1.59B | 0.49% | 68Neutral |
 DAX | $44.51 | $53.75(20.76% Upside) | $204.03M | 0.20% | 68Neutral |
 FLEE | $38.08 | $45.10(18.44% Upside) | $99.74M | 0.09% | 64Neutral |
 FLSW | $44.40 | $46.76(5.34% Upside) | $92.69M | 0.09% | 70Neutral |
 FLGR | $32.59 | $38.96(19.54% Upside) | $37.86M | 0.09% | 68Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FGM | First Trust Germany AlphaDEX Fund | 57.54 | -0.22 | -0.37% | |
| EWG | iShares MSCI Germany ETF | 41.88 | 1.78 | 4.43% | |
| DAX | Global X DAX Germany ETF | 44.51 | 1.24 | 2.86% | |
| FLEE | Franklin FTSE Europe ETF | 38.08 | 4.13 | 12.17% | |
| FLSW | Franklin FTSE Switzerland ETF | 44.40 | 7.07 | 18.94% | |
| FLGR | Franklin FTSE Germany ETF | 32.59 | 1.34 | 4.27% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.